What Is Vesilute?
Vesilute is a synthetic tetrapeptide bioregulator developed by Professor Vladimir Khavinson’s group at the St. Petersburg Institute of Bioregulation and Gerontology, designed to selectively modulate gene expression in the epithelial and smooth muscle cells of the bladder and lower urinary tract. It belongs to the same family of short peptide bioregulators as Vesugen (blood vessels), Testagen (testes), and Prostamax (prostate gland). It was developed by Prof. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology.
The Khavinson framework posits that organ-derived tetrapeptides carry sequence complementarity to interact with tissue-specific DNA regulatory elements, effectively signaling aging cells to restore more youthful patterns of gene transcription. Vesilute targets the urothelium (bladder lining epithelium) and the detrusor smooth muscle, with proposed research applications in age-related bladder dysfunction, urinary incontinence, and bladder tissue restoration following infection or inflammation.
Vesilute is not approved as a therapeutic agent in the United States or European Union and is available for research use only (RUO).
Mechanism of Action
Vesilute is proposed to act through sequence-specific DNA binding in urothelial and smooth muscle cells of the bladder wall. Khavinson’s laboratory model identifies short peptide bioregulators as molecules capable of minor-groove DNA interaction at complementary nucleotide sequences, altering histone acetylation states and recruiting transcription factors governing proliferation, differentiation, and inflammatory modulation in target tissue.
In the context of bladder biology, the relevant downstream targets include: (1) genes governing urothelial barrier integrity (uroplakins, claudins), which deteriorate with age and recurrent infection; (2) detrusor smooth muscle contractility regulatory genes, which when dysregulated produce overactive bladder (OAB) or underactive bladder phenotypes; and (3) inflammatory mediators including IL-6, TNF-α, and prostaglandin E2, elevated in chronic cystitis and urinary tract aging.
As with other Khavinson bioregulators, Vesilute is not proposed to produce acute pharmacological effects but rather to progressively restore transcriptional profiles toward younger, more functional states over repeated treatment courses.
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Reported Research Time Points
This member section summarizes reported research time points.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Research Citations
- Peptides of pineal gland and thymus prolong human life
Khavinson VKh, Morozov VG. Neuroendocrinology Letters. 2003;24(3–4):233–240. - Gerontological Aspects of Genome Peptide Regulation
Khavinson VKh, Malinin VV. Karger: Basel, 2005. - Peptide regulation of gene expression and functional activity of urothelial cells
Khavinson VKh, Linkova NS, Kozhevnikova E, et al. Bulletin of Experimental Biology and Medicine. 2010. - Peptide bioregulators and aging
Khavinson VKh, Anisimov VN. Biogerontology. 2008;9(2):135–142. - Khavinson development attribution. Stored encyclopedia origin text.
Vesilute is a synthetic tetrapeptide bioregulator developed by Professor Vladimir Khavinson’s group at the St. Petersburg Institute of Bioregulation and Gerontology, designed to selectively modulate gene expression in the epithelial and smooth muscle cells of the bladder and lower urinary tract. It belongs to the same family of short peptide bioregulators as Vesugen (blood vessels), Testagen (testes), and Prostamax (prostate gland).